Genentech, Inc.
NEWS
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
It was a very busy week for clinical trial news. Here’s a look.
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, Genentech’s chief medical officer and head of Global Product Development.
Genentech announced positive topline results from its pivotal Part 2 of the FIREFISH study looking at risdiplam in infants aged 1-7 months with Type 1 SMA.
There were plenty of clinical trial announcements this week. Here’s a look.
JOBS
IN THE PRESS